Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

ACC 2024 Congress

Catch up on all the top stories and latest evidence in cardiology research with our ACC 2024 Congress hub page.
ADVANCED SEARCH
Log in
Top
Cancer Immunology, Immunotherapy
Published in: Cancer Immunology, Immunotherapy 6/2002

01-08-2002 | Original Article

Eliciting cytotoxic T lymphocytes against acute myeloid leukemia-derived antigens: evaluation of dendritic cell–leukemia cell hybrids and other antigen-loading strategies for dendritic cell-based vaccination

Authors: Joanna Galea-Lauri, David Darling, Ghulam Mufti, Phillip Harrison, Farzin Farzaneh

Published in: Cancer Immunology, Immunotherapy | Issue 6/2002

Login to get access
Metadata
Title
Eliciting cytotoxic T lymphocytes against acute myeloid leukemia-derived antigens: evaluation of dendritic cell–leukemia cell hybrids and other antigen-loading strategies for dendritic cell-based vaccination
Authors
Joanna Galea-Lauri
David Darling
Ghulam Mufti
Phillip Harrison
Farzin Farzaneh
Publication date
01-08-2002
Publisher
Springer-Verlag
Published in
Cancer Immunology, Immunotherapy / Issue 6/2002
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-002-0284-4

Other articles of this Issue 6/2002

Cancer Immunology, Immunotherapy 6/2002 Go to the issue

Original Article

Molecular requirements for CD8-mediated rejection of a MUC1-expressing pancreatic carcinoma: implications for tumor vaccines

Letter to the Editors

Immunogenicity of WT-1 peptides

Review

Immature myeloid cells and cancer-associated immune suppression

Original Article

Effect of the dose and composition of an autologous hapten-modified melanoma vaccine on the development of delayed-type hypersensitivity responses

Original Article

Hsp110 over-expression increases the immunogenicity of the murine CT26 colon tumor

Original Article

Linkage of CD40L to a self-tumor antigen enhances the antitumor immune responses of dendritic cell-based treatment
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits